A Trial of Eptinezumab in Participants With Migraine and Insufficient Response to Anti-CGRP Medications

Summary

The main goal of this trial is to learn whether eptinezumab improves migraine symptoms and quality of life of participants with migraine who did not perceive a sufficient improvement during previous treatment with therapies targeting calcitonin gene-related peptide (CGRP).

Timeline

Start

2024-12-18

Primary completion

2026-06-05

Completion

2026-06-05

Drugs

Indications